PR Newswire BiotechOriginal article
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
Phase 1positiveTTX-MC138Positive
AI Analysis
Summary
TransCode Therapeutics completed its Phase 1a clinical trial for TTX-MC138, demonstrating no dose-limiting toxicities and durable disease stabilization in metastatic cancer patients. The company is advancing the RNA therapeutic candidate into Phase 2 development for ctDNA-positive cancers.
Clinical Trial Data
Phase
1a
Primary Endpoint
Met
Outcome Details
No dose-limiting toxicities reported; durable disease stabilization observed in metastatic patients
Importance:6/10
Sentiment:
0.80
Phase 1a completionsafety dataRNA therapeuticsmetastatic cancerdisease stabilizationPhase 2 advancement
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 12:04 PM